From: Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?
Prior lines of chemotherapy | Inclusion biomarkers | Median PFS, months | HR for PFS (95% CI) | P value | ||
---|---|---|---|---|---|---|
Active therapy | Placebo | |||||
Niraparib Monotherapy | ||||||
NOVA [38] | ≥2 | None Patients stratified according to gBRCA status and HRD score | gBRCA: 21.0 | 5.5 | 0.27 (0.17–0.41) | <0.001 |
Non-gBRCA: 9.3 | 3.9 | 0.45 (0.34–0.61) | <0.001 | |||
HRD-positive: 12.9 | 3.8 | 0.38 (0.24–0.59) | <0.001 | |||
HRD-negative: 6.9 | 3.8 | 0.58 (0.36–0.92) | 0.02 | |||
Olaparib Monotherapy | ||||||
SOLO-2 [39] | ≥2 | BRCA1/2 mutation | 30.2 | 5.5 | 0.25 (0.18–0.35) | <0.001 |
Rucaparib Monotherapy | ||||||
≥3a | None | BRCA mutation: 16.6 HRD-positive: 13.6 ITT population: 10.8 | 5.4 5.4 5.4 | 0.23 0.32 0.36 | <0.001 <0.001 <0.001 |